Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2014

Study Completion Date

April 30, 2016

Conditions
Breast CancerFatigueSleep Disorders
Interventions
DRUG

Tamoxifen

DRUG

triptorelin

DRUG

Exemestane

Trial Locations (15)

11030

Don Monti Comprehensive Cancer Center at North Shore University Hospital, Manhasset

28025

Batte Cancer Center at Northeast Medical Center, Concord

28801

Mission Hospitals - Memorial Campus, Asheville

30309

Piedmont Hospital, Atlanta

30342

CCOP - Atlanta Regional, Atlanta

46601

CCOP - Northern Indiana CR Consortium, South Bend

80528

Front Range Cancer Specialists, Fort Collins

95819

Mercy General Hospital, Sacramento

06856

Norwalk Hospital, Norwalk

30342-1611

Northside Hospital Cancer Center, Atlanta

30342-1701

Saint Joseph's Hospital of Atlanta, Atlanta

03301

New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care, Concord

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

V1Y 5L3

British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna

K1H 1C4

Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Breast Cancer Trials, Australia and New Zealand

OTHER

collaborator

Cancer and Leukemia Group B

NETWORK

lead

ETOP IBCSG Partners Foundation

NETWORK

NCT00659373 - Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02 | Biotech Hunter | Biotech Hunter